PR Newswire
PALO ALTO, Calif.
,
May 26, 2021
/PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that
David Cory
, President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Healthcare Conference on
Wednesday, June 2, 2021
at
4:00 PM EDT
.
A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at
www.eigerbio.com
under the “Investors” tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger will also host virtual one-on-one meetings with investors.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
Eiger’s lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.
Zokinvy
®
for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company’s first FDA approved product. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).
For additional information about Eiger and its clinical programs, please visit
www.eigerbio.com
.
Investors and Media:
Sri Ryali
Chief Financial Officer
Email:
[email protected]
Phone: 1-650-272-6138
View original content to download multimedia:
http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-2021-301300252.html
SOURCE Eiger BioPharmaceuticals, Inc.
